Urothelial cancer
Drug research and approvals for urothelial cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 243 studies of urothelial cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 58 drug trials for it since 2013, and FDA has 1 approved and 2 open orphan designations naming it.
- Recruiting worldwide: 243
- Trials authorized in Canada: 58
- FDA orphan approvals: 1
- EU medicines: 0
- Risk-Enabled Therapy After Initiating EV/Pembro for Bladder CancerNCT07908979 · Phase 2 · Fox Chase Cancer Center · starts Oct 16, 2026
- Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin IdentificationNCT07888374 · Not reported · Ruijin Hospital · starts Apr 5, 2026
- A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]NCT07890714 · Phase 1 / Phase 2 · Daiichi Sankyo · starts Oct 16, 2026
- Inactivated UPEC-FimON for Non Muscle Invasive Bladder Cancer After BCG or Intravesical Chemotherapy FailureNCT07881666 · Phase 1 · Hopec Pharma · starts Oct 25, 2025
- 18F-N230A PET/CT Imaging of Nectin-4 Expression in Renal TumorsNCT07875959 · Not applicable · Peking University First Hospital · starts Jul 9, 2026
- Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as Perioperative Systemic Therapy for…NCT07870577 · Not reported · Comprehensive Cancer Center Munich (CCCM) · starts Jun 1, 2026
- BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing…NCT07869836 · Phase 3 · SystImmune Inc. · starts Nov 1, 2026
- Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS)NCT07855926 · Not reported · LMU Klinikum · starts May 17, 2026
- Trop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder SamplesNCT07848854 · Phase 2 · Yunnan Cancer Hospital · starts Aug 1, 2026
| May 22, 2026 | A phase III, open-label, randomised, multicentre, global study of adjuvant datopotamab deruxtecan in combination with rilvegostomig in participants with…Datopotamab deruxtecan (dato-dxd, DS-1062A) / Rilvegostomig (AZD2936) | AstraZeneca Pharmaceuticals | Ongoing |
| Feb 27, 2026 | A phase 3, randomized, open-label study of sacituzumab tirumotecan (MK-2870) carcinoma versus investigator’s choice of non-platinum chemotherapy in…Sacituzumab tirumotecan (MK-2870, SKB264) | Merck & Co. (MSD) | Ongoing |
| Dec 4, 2025 | Forager-2: a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of vepugratinib combined with enfortumab vedotin…Vepugratinib (LY3866288) / Padcev (enfortumab vedotin) / Keytruda… | Eli Lilly | Pending |
| Sep 25, 2025 | A randomized, open-label, phase 2/3 study of datopotamab deruxtecan (DATODXD) plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in…Datopotamab deruxtecan (DS-1062A, dato-dxd) / Carboplatin injection / Cisplatin… | Daiichi Sankyo | Pending |
| Sep 23, 2025 | Izabright-bladder01: a randomized, open-label, phase 2/3 trial of izalontamab brengitecan versus platinum-based chemotherapy for metastatic urothelial cancer…BMS-986507 / Carboplatin bendalis / Ribozar / Cisplatin hikma | Bristol-Myers Squibb | Ongoing |
| May 30, 2025 | A phase 1/2, single-arm, open-label trial to evaluate the safety and efficacy of nadofaragene firadenovec instilled to the renal pelvis in adult subjects with…Adstiladrin | Ferring Pharmaceuticals | Ongoing |
| Nov 7, 2024 | Modern: an integrated phase 2/3 and phase 3 trial of mrdbased optimization of adjuvant therapy in urothelial cancerOpdivo / BMS-986016 | Canadian Cancer Trials Group, Cancer Research Institute, Queen's University | Ongoing |
| Jul 12, 2024 | Phase Ib trial of erdafitinib combined with enfortumab vedotin following platinum and PD1/L1 inhibitors for metastatic urothelial carcinoma with FGFR2/3…Erdafitinib | University Health Network | Closed |
| Feb 21, 2024 | A randomized open-label phase 2/3 study of BT8009 as monotherapy or in combination in participants with locally advanced or metastatic urothelial cancer…Zelenectide pevedotin (BT8009) / Pembrolizumab / Carboplatin / Avelumab /… | Bicycletx Limited | Ongoing |
| Nov 6, 2023 | A phase 2/3 multicenter trial evaluating the safety and efficacy of ST-02 on ablation of urothelial carcinomas in the upper urinary tractGemcitabine (ST-02) | Dr. Peter Black | Ongoing |
| Apr 15, 2020 | JelmytoJELMYTO® is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC) | UroGen Pharma, Ltd. | Approved |
| Mar 2, 2021 | PadeliporfinTreatment of upper tract urothelial cancer | Steba Biotech S.A | Designated |
| Dec 22, 2004 | PaclitaxelTreatment of non-superficial urothelial cancer | Sonus Pharmaceuticals, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA